The estimates of relative bioavailability of new SR with IR formulation based on dose-adjusted AUC0-inf were 91 % ( 0.86-0 .96 ) for the fasted state and 99 % ( 0.95-1 .02 ) for the fed state , while these estimates comparing new SR with ER formulation were 99 % ( 0.96-1 .03 ) in the fasted state and 98 % ( 0.95-1 .02 ) in the fed state .